RECURSION PHARMACEUTICALS, INC. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Recursion Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Recursion Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$98.4M, a 1.2% increase year-over-year.
  • Recursion Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$394M, a 26.3% decline year-over-year.
  • Recursion Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$350M, a 42.5% decline from 2022.
  • Recursion Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$246M, a 34.4% decline from 2021.
  • Recursion Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$183M, a 116% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$350M -$104M -42.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-29
2022 -$246M -$63M -34.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-29
2021 -$183M -$98.2M -116% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-29
2020 -$84.6M -$22.2M -35.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 -$62.4M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.